AGBT 2024

Reveal the power of the 6-base genome – Introducing duet multiomics solution evoC

Distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) together with all 4 canonical bases to measure multiple modes of biology from a single 5ng DNA sample in a single experiment.

2 February 2024
Caribe Royale Orlando, Orlando

About the event

The General Meeting is AGBT’s flagship event for bringing together global leaders, researchers, and innovators.

Advances in Genome Biology and Technology (AGBT) delivers a premier experience where heads of labs, institutions, businesses, financial analysts and other high-level stakeholders come together to advance the field and drive game-changing innovation. Significant scientific advances are announced and showcased, science and industry forge enduring partnerships, and significant investments and notable acquisitions are made.

Find the venue

Presenting at the event

Deep, targeted simultaneous sequencing of genetics and epigenetics in DNA

Jack Monahan, Ph.D

Senior Bioinformatics Scientist

biomodal

Poster #544 | Tuesday, Feb. 6, 2024 | 1:30 pm EST - 3:30 pm EST

Presentation abstract

DNA comprises molecular information stored in genetic and epigenetic bases, both of which are vital to our understanding of biology. The interplay between genetics and the DNA epigenome orchestrates complex biological phenomena as diverse as cell fate, ageing, the response to environmental stimuli, and disease pathogenesis. Methods widely used in the detection of methylated cytosines fail to discriminate between thymines and unmodified cytosines. Consequently, they fail to capture common C-to-T transitions and provide incomplete genetic information. The duet multiomics solution is a new technology which sequences at single base resolution the complete genetic sequence integrated with modified cytosine. 

Refining liquid biopsy: Generating more information from cell free DNA

Tom Charlesworth, Ph.D.

Director of Market Strategy & Corporate Development

biomodal

Poster #620 | Tuesday, Feb. 6, 2024 | 1:30 pm EST - 3:30 pm EST

Presentation abstract

Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtypeHowever, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumour is a small minority. Therefore, we are faced with a dilemma when utilising the limited sample to obtain maximum information.  

Measuring genetics, 5mC and 5hmC at single-base resolution

Walraj S. Gosal, Ph.D.

Associate Director of Discovery

biomodal

Poster #602 | Tuesday, Feb. 6, 2024 | 1:30 pm EST - 3:30 pm EST

Presentation abstract

DNA comprises molecular information stored in genetic and epigenetic bases, both of which are vital to our understanding of biology. In human genomes, an epigenetic modification at the fifth carbon of cytosines bases comprises one fundamental pathway by which genes can be silenced or activated. Methods widely used to detect epigenetic modifications at cytosine bases rely on either deamination of unmodified cytosines to read as thymine or borane reduction of the modified oxidised cytosine bases to read as thymine. As a result, such methods fail to capture common C-to-T mutations, and importantly also fail to distinguish 5-methylcytosine (5mC – mainly found in silenced parts of the genome) from 5-hydroxymethylcytosine (5hmC – enriched in active gene bodies and enhancers). Hence, existing methods are unable to read the complete information stored in our genomes in a single workflow.  

AGBT Feb 2024

Register your interest

Cambridge Epigenetix is now biomodal